All In Biotech

Drug Trial Radar · NCT02811185

Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose

An Open-label, Non-randomized Study to Monitor for Adverse Drug Reactions Among Patients Administered Fedoruk-manufactured [F-18]-FDG Injection

Last checked: Nov 20, 2026Latest source record: May 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,012

Actual

Start

Jun 2016

Primary completion

Jan 2017

Study completion Jan 30, 2017

Sponsor

Lead sponsor
University of SaskatchewanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sylvia Fedoruk Canadian Centre for Nuclear Innovation; Saskatoon Health Region
First posted
Jun 23, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-centre, open-label, non-randomized clinical trial designed to monitor the occurrence of adverse events associated with \[F-18\]-FDG Injection manufactured by the Fedoruk Centre. \[F-18\]-FDG Injection used in this clinical trial will be identical to commercial \[F-18\]-FDG that is already used at Royal University Hospital (RUH).

Conditions

  • Positron-Emission Tomography and Cone-Beam Computed Tomography

Interventions

  • [F-18]-FludeoxyglucoseDrug

    Radiopharmaceutical imaging agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Document any adverse drug reactions, following administration of [F-18]-FDG Injection.Time frame: 1 day

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.